Evidence map›Paper›PMID 38535610›Full record

ArticlePathogens (Basel, Switzerland)2024

The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.

Mateusz Babicki, Damian Kołat, Żaneta Kałuzińska-Kołat, Joanna Kapusta, Agnieszka Mastalerz-Migas, Piotr Jankowski, Michał Chudzik

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mateusz BabickiDepartment of Family Medicine, Wroclaw Medical University, 51-141 Wroclaw, Poland.ORCID 0000-0002-7719-6959
Damian KołatDepartment of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland.ORCID 0000-0002-1086-3796
Żaneta Kałuzińska-KołatDepartment of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland.ORCID 0000-0002-2335-3293
Joanna KapustaDepartment of Internal Diseases, Rehabilitation and Physical Medicine, Medical University of Lodz, 90-647 Lodz, Poland.ORCID 0000-0002-5082-3641
Agnieszka Mastalerz-MigasDepartment of Family Medicine, Wroclaw Medical University, 51-141 Wroclaw, Poland.ORCID 0000-0001-6600-2760
Piotr JankowskiDepartment of Internal Medicine and Geriatric Cardiology, Medical Centre for Postgraduate Education, 01-813 Warsaw, Poland.ORCID 0000-0001-6223-8821
Michał ChudzikDepartment of Internal Medicine and Geriatric Cardiology, Medical Centre for Postgraduate Education, 01-813 Warsaw, Poland.ORCID 0000-0001-8805-9688
Medical University of Lodz · PLWroclaw Medical University · PLPostgraduate School of Molecular Medicine · PL

Funding

The Medical Center of Postgraduate Education. The Medical Center of Postgraduate Education.
6 · The paper itself

Abstract

SARS-CoV-2 has acquired many mutations that influence the severity of COVID-19's course or the risk of developing long COVID. In 2022, the dominant SARS-CoV-2 variant was Omicron. This study aimed to compare the course of COVID-19 in the periods before and during the dominance of the Omicron variant. Risk factors for developing long COVID were also assessed. This study was based on stationary visits of patients after COVID-19 and follow-up assessments after 3 months. Clinical symptoms, comorbidities, and vaccination status were evaluated in 1967 patients. Of the analyzed group, 1308 patients (66.5%) were affected by COVID-19 in the period before the Omicron dominance. The prevalence of long COVID was significantly lower among patients of the Omicron group (47.7% vs. 66.9%,

Indexed as

COVID-19SARS-CoV-2AdultAgedAsthmaComorbidityFemaleHumansMaleMiddle AgedPost-Acute COVID-19 SyndromePrevalenceRisk FactorsCOVID-19long COVIDOmicronpre-Omicronrisk factors

Identifiers

PMID38535610
PMCPMC10975347
OpenAlexW4392986843

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.